Treatment Outcome of Ovulation-inducing Agents in Patients with Anovulatory Infertility: A Prospective, Observational Study

Overview

Journal J Pharmacol Pharmacother

Specialty Pharmacology

Date 2017 Oct 31

PMID 29081619

Citations 1

Authors

Kinjal Prajapati

Mira Desai

Samidh Shah

Sumesh Choudhary

Rohina Aggarwal

Vineet Mishra

Affiliations

Soon will be listed here.

Abstract

Objective: To compare different treatment regimens on pregnancy rate and outcome in patients with anovulatory infertility.

Patients And Methods: A prospective observational study was conducted on patients with infertility due to anovulation. Patients treated with clomiphene citrate (CC) 50/100 mg/day from 2 to 6 day of menstrual cycle (MC) ( = 38), short gonadotropin-releasing hormone (GnRH) agonist regimen (leuprolide [0.5 mg subcutaneous] + recombinant follicle-stimulating hormone [rFSH] [225 IU intramuscular [IM] from 2 to 10 day of MC [ = 32]), long GnRH agonist regimen (leuprolide from 21 day followed by leuprolide + rFSH from 2 to 10 day of MC [ = 19]), and antagonist regimen (human menopausal gonadotropin [hMG] [150 IU IM] from 2 day followed by hMG + cetrorelix from 7 to 10 day of MC) ( = 6) were recruited and followed up for follicular size, endometrial thickness, and pregnancy test. Data were analyzed using appropriate statistical test andP < 0.05 was considered statistically significant.

Results: A significant increase in follicular diameter and endometrial thickness was observed in patients treated with gonadotropin regimens as compared to CC alone ( < 0.0001). The highest number of positive pregnancy test with ultrasonographic evidence of gestational sac was observed with leuprolide + rFSH (long regimen) (10/19, 52.6%) followed by leuprolide + rFSH (short regimen) (13/32, 40.6%) while least in antagonist regimen (2/6, 33.3%) and CC (1/38, 2.63%). All regimens were well tolerated.

Conclusion: Treatment outcome was better with long agonist regimen.

Citing Articles

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.

Velthuis E, Hubbard J, Longobardi S, DHooghe T Adv Ther. 2020; 37(12):4831-4847.

PMID: 33058045 PMC: 7595967. DOI: 10.1007/s12325-020-01512-w.

References

Al-Inany H, Abou-Setta A, Aboulghar M . Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007; 14(5):640-9. DOI: 10.1016/s1472-6483(10)61059-0. View

Orvieto R, Meltcer S, Homburg R, Nahum R, Rabinson J, Ashkenazi J . What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?. Fertil Steril. 2008; 91(4 Suppl):1466-8. DOI: 10.1016/j.fertnstert.2008.07.1711. View

Shalom-Paz E, Marzal A, Wiser A, Hyman J, Tulandi T . Does optimal follicular size in IUI cycles vary between clomiphene citrate and gonadotrophins treatments?. Gynecol Endocrinol. 2013; 30(2):107-10. DOI: 10.3109/09513590.2013.860126. View

Leao R, Esteves S . Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics (Sao Paulo). 2014; 69(4):279-93. PMC: 3971356. DOI: 10.6061/clinics/2014(04)10. View

Hsu W, Araneta M, Kanaya A, Chiang J, Fujimoto W . BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care. 2014; 38(1):150-8. PMC: 4392932. DOI: 10.2337/dc14-2391. View

Ombelet W, Martens G, De Sutter P, Gerris J, Bosmans E, Ruyssinck G . Perinatal outcome of 12,021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study. Hum Reprod. 2005; 21(4):1025-32. DOI: 10.1093/humrep/dei419. View

Al-Inany H, Abou-Setta A, Aboulghar M, Mansour R, Serour G . Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008; 16(1):81-8. DOI: 10.1016/s1472-6483(10)60559-7. View

Dasari P, Pranahita G . The efficacy of metformin and clomiphene citrate combination compared with clomiphene citrate alone for ovulation induction in infertile patients with PCOS. J Hum Reprod Sci. 2009; 2(1):18-22. PMC: 2700688. DOI: 10.4103/0974-1208.51337. View

Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A . Obesity and reproductive disorders in women. Hum Reprod Update. 2003; 9(4):359-72. DOI: 10.1093/humupd/dmg024. View

10.

Legro R . Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012; 30(6):496-506. PMC: 3649566. DOI: 10.1055/s-0032-1328878. View

11.

Hart R, Hickey M, Franks S . Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004; 18(5):671-83. DOI: 10.1016/j.bpobgyn.2004.05.001. View

12.

Palatnik A, Strawn E, Szabo A, Robb P . What is the optimal follicular size before triggering ovulation in intrauterine insemination cycles with clomiphene citrate or letrozole? An analysis of 988 cycles. Fertil Steril. 2012; 97(5):1089-94.e1-3. DOI: 10.1016/j.fertnstert.2012.02.018. View

13.

Norman R, Dewailly D, Legro R, Hickey T . Polycystic ovary syndrome. Lancet. 2007; 370(9588):685-97. DOI: 10.1016/S0140-6736(07)61345-2. View

14.

Zegers-Hochschild F, Adamson G, de Mouzon J, Ishihara O, Mansour R, Nygren K . The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009. Hum Reprod. 2009; 24(11):2683-7. DOI: 10.1093/humrep/dep343. View

15.

Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt P, van Wely M . Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2007; 23(2):310-5. DOI: 10.1093/humrep/dem305. View